Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: PODEMSKI
Liczba odnalezionych rekordów: 3



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/3

Tytuł oryginału: An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
Autorzy: Bilikiewicz Adam, Opala Grzegorz, Podemski Ryszard, Pużyński Stanisław, Łapin Joanna, Sołtys Krzysztof, Ochudło Stanisław, Barcikowska Maria, Pfeffer Anna, Bilińska Małgorzata, Paradowski Bogusław, Parnowski Tadeusz, Gabryelewicz Tomasz
Źródło: Med. Sci. Monitor 2002: 8 (2) s.PI9-PI15, il., tab., bibliogr. 22 poz.
Sygnatura GBL: 313,278

Hasła klasyfikacyjne GBL:
  • toksykologia
  • neurologia

    Typ dokumentu:
  • praca kliniczna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • dorośli 45-64 r.ż.
  • dorośli = 65 r.ż.
  • płeć męska
  • płeć żeńska

    Streszczenie angielskie: Background: Long-term safety and efficacy of Exelon (rivastigmine) was evaluated in a multi-center open label study of 62 patients with probable mild to moderated Alzheimer's disease living in community setting. Material/Methods: The patients started treatment with 1.5 mg bid (3 mg/day) Exelon and were scheduled to receive doses of 1.5 mg bid Exelon escalating on a biweekly basis. The patients were maintained on the highest tolerated dose within the assigned dose range 1.5 - 60.0 mg bid (3 - 12 mg/day) for the rest of the study. Evaluations were scheduled at biweekly intervals for the first 8 weeks and subsequently at study weeks 12, 18 and 26. Effects of Exelon on cognition were evaluated using the mini-mental state examination (MMSE) and selected items of Alzhemier's disease assessment scale (ADAS-cog) and the staging ot the disease was measured using the global deterioration scale (GDS). Safety was monitored by physical examinations, vital signs, laboratory tests, ECG recording and by the assessment of adverse events. Resutls: 55 patients completed the study (89 p.c.). Patients treated for 26 weeks showed the mean MMSE, ADAS-cog and GDS scores close to baseline values (p = NS) with no improvement and no deterioration. Exelon was generally well tolerated with 11 p.c. of patients withdrawing due to adverse events. The most frequently reported adverse events related to the gastrointestinal tract. Conclusions: In conclusion, the study data indicate that treatment with Exelon is safe, generally well tolerated and inhibits the progression of cognitive decline in patients wtih mild to moderate Alzheimer's disease over 26 weeks of treatment.

    2/3

    Tytuł oryginału: Serum levels of sTNFR-1 and sFas in patients with relapsing-remitting multiple sclerosis.
    Autorzy: Bilińska Małgorzata, Frydecka Irena, Podemski Ryszard, Gruszka Ewa
    Źródło: Med. Sci. Monitor 2002: 8 (10) s.CR720-CR723, tab., bibliogr. 32 poz.
    Sygnatura GBL: 313,278

    Hasła klasyfikacyjne GBL:
  • immunologia
  • neurologia

    Typ dokumentu:
  • praca kliniczna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • dorośli 19-44 r.ż.
  • dorośli 45-64 r.ż.

    Streszczenie angielskie: Background: During the relapse of multiple sclerosis (MS), activated T cells, T cells autoreactive against myelin antigens as well as antigen-nonspecific lymphocytes and monocytes produce a number of proinflammatory cytokines such as TNF (Tumor Necrosis Factor). For a proinflammaoty effect to take place TNF must bind together with appropriate receptors. The aim of the study was to assess value of serum sTNFR-1 adn sFas levels with reference to clinical activation of disease. Material/Methods: Thirty-three patients with clinically documented diagnosis of relapsing-remitting MS and 22 healthy subjects were included in the study. In 15 patients the measurements of sTNFR-1 and sFas levels were performed at the beginning of MS relapse and in 18 subjects - they were taken in MS remission. The levels of both soluble molecules were determined with the use of enzyme-linked immunosorbent assay (ELISA). Results: Mean serum sTNFR-1 levels in patients with MS relapse did not differe significantly from mean sTNFR-1 level in patients with MS remission and a control group. Mean serum sFas level in patients with MS relapse was significantly higher comparing with the results obtained in patients with MS remission and in control group. Conslusions: The absence of changes in serum sTNFR-1 levels relative to clinical activation of the disease makes this measurement ineffective in the assessment of MS status. On the other hand, the measurement of serum sFas levels may be a valuable parameter for the monitoring of both MS clinical couse and immune response to treatment when the symptoms of neurological aggravate.

    3/3

    Tytuł oryginału: Patofizjologia i leczenie czkawki.
    Tytuł angielski: Pathophysiology and treatment of hiccup.
    Autorzy: Budrewicz Sławomir, Góral Małgorzata, Podemski Ryszard
    Źródło: Prz. Lek. 2002: 59 (11) s.924-926, il., tab., bibliogr. 32 poz., sum.
    Sygnatura GBL: 310,563

    Hasła klasyfikacyjne GBL:
  • pediatria
  • farmacja

    Wskaźnik treści:
  • ludzie

    Streszczenie polskie: Czkawka polega na mimowolnym, napadowym, wdechowym ruchu klatki piersiowej, połączonym ze skurczem przepony i dodatkowych mięśni oddechowych. Problem kliniczny związany jest przede wszystkim z przewlekłą, patologiczną czkawką. Autorzy omawiają patofizjologię czkawki i możliwości diagnostyczne, jak również różnorodne opcje terapeutyczne.

    Streszczenie angielskie: Hiccump is defined as involuntary, paroxymal inspiratory movements of the thoracic wall, together with contraction of the diaphragm and additional respiratory muscles. The clinical problem is connected mainly with pathological chronic hiccup. The authors discuss pathophysiology of hiccup and diagnostic possibilites, as well as various therapeutical options.

    stosując format: